Patent · US Active

Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof

US9655914B2 · kind B2 · utility

0Cited by

22References

19Claims

0Family size

Assignee

University of South Florida · US

Inventors

Jin Q. Cheng · Tampa, US
Said M. Sebti · Tampa, US

Key dates

Filing date	Dec 28, 2015
Grant date	May 23, 2017
Priority date	—
Expiry date	Dec 28, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/912
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.